The potential effects of α-synuclein-induced inhibition remain to be examined on other nAChR subtypes, such as hα6β2-, hα6β2β3- and hα3β4-nAChR, which may serve as a potential target for PD therapeutics as well. The gene discussed is CHRNA4; the disease is Parkinson disease.